CaniShot Cv
Canine Corona Virus Vaccine, Inactivated I.P.
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Brand name
- CaniShot
- Payment Terms
- L/C,Others,T/T
- Production method
- Available,OEM
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- animal vaccine, canishot, cv, canine vaccine
- Category
- Veterinary Medicine
ChoongAng Vaccine Laboratories Co., Ltd.(CAVAC)
- Verified Certificate
-
16
Product name | CaniShot Cv | Certification | - |
---|---|---|---|
Category | Veterinary Medicine | Ingredients | ADJUVANT,iNACTIVATED CANINE CORONAVIRUS |
Keyword | animal vaccine , canishot , cv , canine vaccine | Unit Size | - |
Brand name | CaniShot | Unit Weigh | - |
origin | South Korea | Stock | 0 |
Supply type | Available,OEM | HS code | 300230 |
Product Information
Mixable inactivated coronavirus vaccine
CaniShot® Cv
Indication
An aid in the control and prevention of coronavirus infection in dogs.
Composition and quantity (per dose)
CaniShot® Cv
Inactivated canine coronavirus (K-378 strain)...................≥106.0TCID50
Adjuvant…………………………………………….…............10%
Features
Can be mixed with CaniShot® K5.
Excellent prevention against viral enteritis.
Antigens developed and verified by Cornell University are used.
Reduces the frequency of vaccination.
Minimized side effect through using easily absorbable adjuvant.
Administration and dosage
Administer 1 dose (1.0㎖) on the scapular region (shoulder area) subcutaneously.
- Vaccination age
① 1st vaccination : 6~7 weeks of age
② 2nd vaccination : 8~9 weeks of age
③ 3rd vaccination : 11 ~14 weeks of age
④ Booster vaccination : once every year
Packaging unit
1 dose/vial
- Product Info Attached File
B2B Trade
Price (FOB) | Negotiable | transportation | Air Transportation,Negotiation Other,Ocean Shipping |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | L/C,Others,T/T | Shipping time | Negotiable |
- President
- Injoong Yoon
- Address
- 1476-37 Yuseong-daero, Yuseong-gu, Daejeon, Korea
- Product Category
- Veterinary Medicine
- Year Established
- 1968
- No. of Total Employees
- 101-500
- Company introduction
-
As an innovative animal vaccine company, CAVAC’s long journey with continuing efforts
CAVAC leads the way in animal health
CAVAC is a powerful leader in the field of animal biological products. We provide a wide range of groundbreaking pharmaceutical products that promote animal health and welfare, as well as improving the quality of life of people in Korea.
CAVAC’s long history and continued efforts
Since it was founded in 1968, CAVAC has grown to become renowned in Korea as a developer and manufacturer of animal vaccines. With over 80 animal vaccine products, the company is a key player in the Korean and global markets. We have achieved multiple vendor audits conducted by multinational companies and government audits. CAVAC is also committed to finding better solutions for pharmaceutical, biological and diagnostic products, and strives to be a pioneering partner offering a wide range of services.
Global bio leader in the advanced animal vaccine industry
As an animal vaccine company, CAVAC has experienced accelerated growth. As well as enhancing the development of new products and technologies, we have maximized our investments to protect against challenges and competition from various global companies. CAVAC is strategically located in the Daedeok Innopolis, also known as the Silicon Valley of Korea, and has teamed up with a number of prominent research institutions. CAVAC is now expanding onto the global market and is striving to become one of the top 10 global partners in animal health.
- Main Markets
-
Bangladesh
Cambodia
Indonesia
Myanmar
Nepal
Pakistan
Philippines
Thailand
Viet Nam
- Factory Information
-
(주)중앙백신연구소,
주식회사 중앙백신연구소
- Main Product
Related Products
h-respi - feed additives - veterinary medicine
water soluble powder doxycycline hcl 10%
TRILOSIN Powder / Tylosin Tartrate
URIVET10
Valnemulin Hydrochloride Premix 10%